Arkolith/Insider Trading/AUPH/Form 4

Greenleaf Peter

Chief Executive Officer, DirectorAurinia Pharmaceuticals Inc. (AUPH) · full profile →Form 4 · filed Mar 4, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.9M
Net Open-Market Flow
-$2.9M
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 4, 2025Sell(S)165K$7.92$1.3M1.8M
Mar 3, 2025Sell(S)196K$8.00$1.6M2.0M
Mar 3, 2025Grant(A)334K—$02.1M
Feb 28, 2025Grant(A)291K—$01.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 28, 2025Grant(A)444K—$0444K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001600620-25-000024) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML